Effective June 3, 2020, stavudine (Zerit®), has been removed from the ADAP formulary. ADAP received a manufacturer notification stating that the sale and distribution of stavudine, a nucleoside analog reverse transcriptase inhibitor, would cease by March 31, 2020. Though stavudine will continue to be available generically, the ADAP Medication Advisory Committee recommended the removal of both brand and generic stavudine due to the toxicity of this medication and the availability of alternatives on the ADAP formulary that are less toxic and more effective.
ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the removal of Zerit®. Access to the updated formulary is available at the following URL: https://cdph.magellanrx.com/member/documents.
If you have any questions regarding the addition of these medications to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.
Sandra Robinson, MBA
ADAP Branch Chief
California Department of Public Health